DVAd
Vaya mugiwara OTRA PA TI Y despues dices que yo exageroooooo, jooo que cada vez que leo un art pumpista de estos me dan deseos de subir mi PO, je,je,je
The success of Gilead Sciences (NASDAQ:GILD) in the Hep C space has sparked a great of deal interest in the Hep B space as well. In fact, ....
the Hep B market could turn out to be even bigger than Hep C-- (
Dynavax remains on target to file a revised BLA for Heplisav B early next year. This means that the company will potentially reach commercialization stage by early next year. Given the potential of Heplisav B, it is not surprising to see that investors have been excited about DVAX. Year-to-date, shares have already gained more than 74%, but there could be even more upside as DVAX moves closer to commercialization.
According to GlobalData, the global Hep B vaccine market could reach $1.19 billion by 2022, with the U.S. accounting for nearly 60% of the market. DVAX is initially focusing on the U.S., where it plans to commercialize the drug on its own.
-
If the company is successful in capturing 50% of the total U.S. market of around $600 million by 2022, this would translate to $300 million in sales.
-
Based on just the potential in the U.S., DVAX still looks undervalued despite the nearly 75% gain posted this year.
http://seekingalpha.com/article/3374225-premarket-biotech-digest-familial-hypercholesterolemia-dynavax-bla-track-earnings?app=1&auth_param=ft8lg:1ark5cs:379846458bd72369d355bf5b9042c948&uprof=37